An Adult with Aplastic Crisis induced by Human Parvovirus B19 as an Initial Presentation of Hereditary Spherocytosis

Sook Eui Oh, M.D., Jung Han Kim, M.D., Chi Hun Choi, M.D., Kwang Hyuk Park, M.D., Joo Young Jung, M.D., Young Iee Park, M.D. and Min-Jeong Park, M.D.

Departments of Internal Medicine and Clinical Pathology, College of Medicine, Hallym University, Seoul, Korea

The association between aplastic crisis and human parvovirus (HPV) B19 infection is well described in patients with sickle cell anemia. This association has also been described, although much less frequently, in patients with hereditary spherocytosis (HS). However, most cases of aplastic crises in patients with HS and induced by HPV B19 have been reported in children or adolescents. In this paper, we describe an aplastic crisis induced by HPV B19 in an adult with HS. A 34-year-old female presented with presyncope, febrile sensation, and myalgia. The complete blood counts showed severe anemia. The peripheral blood smear revealed spherocytosis with reticulocytopenia and pancytopenia. The direct Coombs’ test was negative; the osmotic fragility test was positive. In the bone marrow aspirates, a few giant pronormoblasts with deep blue cytoplasm, pseudopods, and intracellular inclusion bodies were observed. The patient was given eight units of packed red blood cells. HPV B19 infection was proven by the presence of IgM antibodies to HPV B19 and the detection of viral DNA using the PCR technique. To the best of our knowledge, this is the first report in Korea that describes an adult with aplastic crisis presenting initially with HS.

Key Words: Aplastic crisis, Hereditary spherocytosis, Parvovirus B19, Pancytopenia

INTRODUCTION

Human parvovirus (HPV) B19 is an encapsulated, minute virus with a single-stranded DNA genome that belongs to the Paroviridae family. Several types of parvovirus cause disease in some animals, but HPV B19 is the only parvovirus which can cause disease in humans. HPV B19 is associated with several clinical syndromes, ranging from subclinical infection to chronic infection or severe hemophagocytic syndrome in immunocompromised patients. HPV B19 has been identified as the cause of erythema infectiosum (fifth disease) in children, and fetal hydrops and spontaneous abortion during pregnancy. This virus also causes acute arthritis and reactive arthropathy in adults.

The association of HPV B19 with aplastic crises in carriers of hereditary hematologic abnormalities is well-documented. Most reported cases have been limited to patients with sickle cell disease. This association has also been described, although much less frequently, in patients with hereditary spherocytosis (HS). Most of the affected patients were children or adolescents with HS which had already been documented prior to aplastic crisis. As in the case of our patient, however, such crisis may be the initial presentation of HS. To the best of our knowledge, this is the first report in Korea which describes an adult with aplastic crisis induced by HPV B19 as an initial presentation of HS.
**CASE REPORT**

A 34-year-old female was admitted to the hospital with the chief complaint of presyncope, which had developed a few hours previously. She also complained of febrile sensation and myalgia which had begun 4 days prior to admission. She had no allergies or past medical history, and her family history was unremarkable. The physical examination revealed a blood pressure of 90/60 mmHg, a pulse rate of 96 beats per minute, a temperature of 37.8°C, and a respiration rate of 18 times per minute. Her skin and conjunctivae were pale, and sclera was yellowish. No evidence of cervical lymphadenopathy or abnormal findings upon chest examination was found. The low margin of the spleen was palpable at 5 cm from the costal margin. The initial complete blood counts were as follows: hemoglobin (Hb) 3.0 g/dL, hematocrit (Hct) 8.4%, MCV 81.7 fl, MCHC 36%, white blood cell (WBC) count 3,160/mm³ (segmented neutrophil 66%, lymphocytes 30.5%, monocytes 1.5%), platelets count 163,000/mm³, and reticulocytes 0.2%. Liver function tests showed an aspartate aminotransferase 81 IU/L, alanine aminotransferase 52 IU/L, total bilirubin 5.2 mg/dL, with indirect bilirubin of 3.5 mg/dL, and lactate dehydrogenase 763 IU/L. Serum iron, total iron binding capacity, and ferritin level were within normal ranges, and haptoglobin had been decreased to 38.0 mg/dL. The peripheral blood smear revealed spherocytosis with reticulocytopenia and pancytopenia (Figure 1). The direct antiglobulin (Coombs) test was negative, and osmotic fragility of patient’s red cells was increased. Bone marrow aspirate smears showed a few giant pronormoblasts with deep blue cytoplasm, pseudopods, and poorly demarcated intranuclear inclusions (Figure 2). These results indicate that the diagnostic hypothesis was an aplastic crisis induced by HPV B19 infection in a patient with underlying HS. Using the patient’s peripheral blood and bone marrow aspirate, we performed polymerase chain reaction (PCR) for the detection of HPV B19 DNA. The PCR of the patient’s materials resulted in an amplification of the 496 base pair (bp) band, which was confirmed by the nested PCR, where a 232 bp band was amplified (Figure 3). The patient was subsequently given eight units of packed red blood cells. During the course of admission, the WBC count decreased to 1,170/mm³ on the 2nd day and platelet count fell to 93,000/mm³ on the 4th day. We requested a serologic test for anti-HPV B19 IgM and IgG antibodies on the 10th day of hospitalization. Hematologic recovery began 12 days after admission. At discharge on the 15th day, the Hb was 8.4 g/dL, Hct 24.3%, WBC count 5,840/mm³, platelet count 233,000/mm³, and reticulocyte 5.1%. HPV B19 serology was pending at the time of discharge. One week later, the patient’s Hb and Hct rose to 10.0 g/dL and 30%, with a reticulocyte count of 10%. Tests for anti-HPV B19 IgM and IgG antibodies were positive.

**DISCUSSION**

HPV B19 lytically infects erythroid progenitor cells and inhibits erythropoiesis, leading to acute erythroblastopenia and reticulocytopenia.[9] When infected with the virus, healthy subjects may develop this to some degree, but the normal erythrocyte life span in these otherwise healthy subjects prevents them from becoming significantly anemic.[5] Although the major targets of
Figure 3. Detection of human parvovirus B19 DNA by polymerase chain reaction (PCR) in blood and bone marrow aspirates. The first PCR resulted in an amplification of 496 base pair (bp) band, confirmed by the nested PCR, where a 232 bp band was amplified. Lane M, DNA size marker; Lane B, blood sample; Lane BM, bone marrow aspirates; Lane N, negative control; Lane P, positive control.

HPV B19 are erythroid progenitor cells, HPV B19–induced bone marrow damage does not exclusively involve a single hematopoietic cell lineage. In addition to reticulocytopenia, neutropenia and thrombocytopenia have been observed in association with HPV B19 infection in patients both with and without hemolytic disorders\(^7,8,11\). Our patient also showed transient pancytopenia. Though not yet clearly explained, neutropenia and thrombocytopenia might be associated with hematophagocytosis or with HPV B19-induced inhibition of hematopoiesis\(^7,12\).

The typical clinical picture of HPV B19 infection and subsequent aplastic crisis includes one or more of the following symptoms: fever, headache, myalgia, and abdominal pain. The length of time between infection and onset of aplastic crisis is known to be eight to ten days. The interval between the onset of symptoms and reappearance of reticulocytes in peripheral blood ranges from five to twenty days\(^{13}\). Fortunately, life-long immunity is generally acquired following infection with HPV B19, so most patients are subjected to no more than one such crisis in a lifetime\(^{16}\). However, such crises may be clinically severe and require prompt red cell transfusion. Our patient fits the classical clinical picture for aplastic crisis caused by HPV B19. After an unspecific presentation of febrile sensation and myalgia, she presented with presyncope which had probably been caused by profound anemia. She was subsequently transfused with red blood cell concentrates because of the severity of aplastic crisis. For patients with prolonged severe aplasia or immunodeficiency, intravenous immunoglobulin infusion for 5 to 10 days can often be recommended\(^8\). However, we chose not to administer immunoglobulin to our patient without immunodeficiency. Her hematologic recovery began at approximately 16 days after the onset of symptoms.

The earliest and most sensitive diagnostic method available is the identification of HPV B19 DNA using PCR in the bone marrow aspirates or blood sample\(^8,14,15\). Serologic tests for anti–HPV B19 IgM antibodies may be another useful diagnostic method\(^14\). Anti–HPV B19 IgM antibodies develop the second week after infection and may be detectable for ≤ 4–6 months. IgG antibodies appear several days after IgM, at the end of the second week or early in the third week. IgG antibodies remain in the system for the rest of the patient’s life, generally signifying past infection. However, HPV B19 DNA amplification using blood samples may be difficult because high-titer viremia lasts only 2 to 3 days\(^8\). Serologic test is incapable of detecting acute infection at the onset of symptoms before the appearance of immunologic response\(^{14}\). Therefore, the contemporaneous determination of HPV B19 DNA by PCR and IgM antibody by serology seems to be the most appropriate diagnostic protocol in order to obtain correct laboratory diagnosis\(^{14}\). In this case, infection with HPV B19 was confirmed both by the detection of HBN DNA using PCR performed on the 3rd day of hospitalization, as well as the presence of anti–HPV IgM antibodies on a serologic test requested on the 10th day.

In the current paper, we described an aplastic crisis induced by HPV B19 in a patient with underlying HS. To the best of our knowledge, this is the first report in Korea that describes an adult with aplastic crisis as an initial presentation of HS.

REFERENCES

1. Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet 1:72–73, 1975
2. Morens DM. Fifth disease: still hazy after all these years. JAMA 248:553–554, 1982
3) Essary LR, Vnencak-Jones CL, Manning SS, Olson SJ, Johanson JE. Frequency of parvovirus B19 infection in nonimmune hydrops fetalis and utility for three diagnostic methods. Hum Pathol 29:696–701, 1998
4) Kandolf R, Kirschner P, Hofachneider PH, Vischer TL. Detection of parvovirus in a patient with reactive arthritis by in situ hybridization. Clin Rheumatol 8:398–401, 1989
5) Young N. Hematologic and hematopoietic consequences of B19 Parvovirus infection. Semin Hematol 25:159–172, 1988
6) Lefrere JJ, Courouce AM, Girot R, Bertrand Y, Soulier JP. Six cases of hereditary spherocytosis revealed by human parvovirus infection. Br J Haematol 62:653–658, 1986
7) Hanada T, Koike K, Takeya T, Nagasawa T, Matsunaga Y, Takita H. Human parvovirus B19-induced transient pancytopenia in a child with hereditary spherocytosis. Br J Haematol 70:113–115, 1988
8) Valera ET, Cipolotti R, Berbardes JE, Pacagnella RC, Lima DM, Tone LG, Fonseca BA. Transient pancytopenia induced by parvovirus B19 in a child with hereditary spherocytosis. J Pediatr 76:323–326, 2000
9) Megason GC, Smith JC, Lyer RV. Aplastic crisis due to human parvovirus (B19) as an initial presentation of hereditary spherocytosis. J Miss State Med Assoc 34:107–109, 1993
10) Mortimer PP, Humphries RK, Moore JG, Purcell RH, Young NS. A human parvovirus–like virus inhibits haematopoietic colony formation in vitro. Nature 302:426–429, 1983
11) Saunders PW, Reid MM, Cohen BJ. Human parvovirus induced cytopenias: a report of five cases. Br J Haematol 63:407–410, 1986
12) Muir K, Todd WT, Watson WH, Fitzsimons E. Viral associated haemophagocytosis with parvovirus B19-related pancytopenia. Lancet 339:1139–1140, 1992
13) Beland SS, Daniel GK, Menard JC, Miller NM. Aplastic crisis associated with parvovirus B19 in an adult hereditary spherocytosis. J Ark Med Soc 94:163–164, 1997
14) Gallinella G, Zuffi E, Gentili G, Manaresi E, Venturoli S, Bonvicini F, Cricca M, Zerbini M, Musiani M. Relavance of B19 Markers in serum samples for a diagnosis of Parvovirus B19-correlated diseases. J Med Virol 71:135–139, 2003
15) Lee YM, Tsai WH, You JY, Ing-Tiau Kuo B, Liao PT, Ho CK Hsu HC. Parvovirus B19 infection in Taiwanese patients with hematological disorders. J Med Virol 71:605–609, 2003